Fort Washington Investment Advisors Inc. OH Trims Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Fort Washington Investment Advisors Inc. OH lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 715,049 shares of the biotechnology company’s stock after selling 451 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in BioMarin Pharmaceutical were worth $50,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in BioMarin Pharmaceutical by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 19,372,185 shares of the biotechnology company’s stock worth $1,273,334,000 after acquiring an additional 93,531 shares in the last quarter. Dodge & Cox lifted its position in shares of BioMarin Pharmaceutical by 6.1% during the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company’s stock worth $969,270,000 after purchasing an additional 847,917 shares during the last quarter. Capital Research Global Investors grew its stake in BioMarin Pharmaceutical by 23.8% in the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company’s stock worth $853,944,000 after purchasing an additional 2,496,817 shares in the last quarter. Norges Bank bought a new stake in BioMarin Pharmaceutical in the fourth quarter valued at about $234,645,000. Finally, Geode Capital Management LLC raised its stake in BioMarin Pharmaceutical by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 3,288,778 shares of the biotechnology company’s stock valued at $215,784,000 after buying an additional 28,728 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Down 0.6%

BioMarin Pharmaceutical stock opened at $57.16 on Thursday. BioMarin Pharmaceutical Inc. has a 12-month low of $52.93 and a 12-month high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The stock has a market capitalization of $10.96 billion, a PE ratio of 25.98, a price-to-earnings-growth ratio of 0.61 and a beta of 0.19. The firm has a 50 day simple moving average of $59.14 and a 200-day simple moving average of $64.11.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BMRN shares. Oppenheimer upgraded BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 target price for the company in a research report on Monday, February 24th. UBS Group lifted their price objective on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. The Goldman Sachs Group lowered their target price on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a “buy” rating for the company in a research note on Monday, May 5th. Bank of America lifted their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a “buy” rating in a report on Thursday, February 20th. Finally, Citigroup lowered their target price on BioMarin Pharmaceutical from $82.00 to $78.00 and set a “neutral” rating for the company in a report on Friday, May 2nd. Six analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $93.45.

Insiders Place Their Bets

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,786 shares of the company’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total value of $105,927.66. Following the completion of the sale, the chief accounting officer now directly owns 14,173 shares of the company’s stock, valued at approximately $840,600.63. This represents a 11.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 3,354 shares of company stock worth $216,269 over the last ninety days. Company insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.